Aura Biosciences (NASDAQ:AURA) SVP Sells $43,257.94 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 8,549 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $43,257.94. Following the completion of the sale, the senior vice president directly owned 75,532 shares in the company, valued at approximately $382,191.92. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 20th, Amy Elazzouzi sold 1,581 shares of Aura Biosciences stock. The stock was sold at an average price of $4.86, for a total transaction of $7,683.66.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $5.36 on Friday. The firm’s 50-day moving average is $5.55 and its two-hundred day moving average is $5.95. The company has a market capitalization of $340.36 million, a PE ratio of -2.76 and a beta of 0.46. Aura Biosciences, Inc. has a 12-month low of $4.34 and a 12-month high of $7.80.

Institutional Trading of Aura Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd lifted its stake in shares of Aura Biosciences by 145.2% during the 4th quarter. XTX Topco Ltd now owns 60,811 shares of the company’s stock worth $331,000 after purchasing an additional 36,006 shares during the period. Wellington Management Group LLP grew its position in shares of Aura Biosciences by 10.7% in the fourth quarter. Wellington Management Group LLP now owns 140,959 shares of the company’s stock valued at $768,000 after purchasing an additional 13,647 shares during the period. Millennium Management LLC increased its stake in Aura Biosciences by 233.3% in the fourth quarter. Millennium Management LLC now owns 617,338 shares of the company’s stock valued at $3,364,000 after purchasing an additional 432,117 shares during the last quarter. Trexquant Investment LP purchased a new position in Aura Biosciences during the fourth quarter worth about $234,000. Finally, ExodusPoint Capital Management LP lifted its position in Aura Biosciences by 18.4% during the fourth quarter. ExodusPoint Capital Management LP now owns 51,419 shares of the company’s stock worth $280,000 after buying an additional 7,998 shares during the period. 96.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on AURA. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 29th. Evercore assumed coverage on Aura Biosciences in a research report on Tuesday, November 25th. They issued an “outperform” rating on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.